Dr. Michael Birrer on Bevacizumab in Ovarian Cancers

December 28, 2015
Michael Birrer, MD, PhD

Michael Birrer, MD, PhD, discusses several international phase III trials showing bevacizumab significantly prolonging progression free survival in patients with ovarian cancer.

Michael Birrer, MD, PhD, director, Medical Gynecologic Oncology Director, Gynecologic Oncology Research Program, Massachusetts General Hospital Cancer Center, professor of Medicine, Harvard Medical School, discusses several international phase III trials showing bevacizumab significantly prolonging progression free survival in patients with ovarian cancer.